Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | RIPK1 | Q13546 | 12/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561665 | 1.00 | GAA (0.57) | GAARIPK1EPHX2IDO1MAPK10 | |
| SCHEMBL1561667 | 1.00 | GAA (0.57) | GAARIPK1EPHX2IDO1MAPK10 | |
| SCHEMBL18368150 | 0.88 | RIPK1 (0.52) | GAARIPK1EPHX2IDO1MAPK10 | |
| SCHEMBL21156863 | 0.88 | RIPK1 (0.52) | GAARIPK1EPHX2IDO1MAPK10 | |
| SCHEMBL1561585 | 0.85 | GAA (0.51) | GAARIPK1EPHX2 | |
| SCHEMBL8904609 | 0.85 | GAA (0.51) | GAARIPK1EPHX2 | |
| SCHEMBL1561583 | 0.85 | GAA (0.51) | GAARIPK1EPHX2 | |
| SCHEMBL17321195 | 0.85 | GAA (0.51) | GAARIPK1EPHX2 | |
| SCHEMBL1562369 | 0.84 | RIPK1 (0.55) | GAARIPK1EPHX2 | |
| SCHEMBL21156864 | 0.84 | GAA (0.50) | GAARIPK1EPHX2IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144715-A1 | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2010-06-10 | — | — | US | disclosed |
| US-20100144715-A1 | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2010-06-10 | — | — | US | disclosed |
| WO-2008106077-A1 | SUBSTITUTED BENZODIAZEPINONES, BENZOXAZEPINONES AND BENZOTHIAZEPINONES AS SODIUM CHANNEL BLOCKERS | MERCK & CO., INC. (US) | 2008-09-04 | — | — | WO | disclosed |
| US-5610153-A | ENZYME INHIBITORS; TREATMENT OF VASCULAR PROLIFERATION DISORDERS, STERILITY DYSFUNCTION, DYSMENORRHEA | CIBA-GEIGY CORPORATION (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0673371-A1 | BENZAZEPINONE DERIVATIVES | Novartis AG (CH) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994013651-A1 | BENZAZEPINONE DERIVATIVES | CIBA-GEIGY AG (CH) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144715-A1 | Substituted Benzodiazepinones, Benzoxazepinones and Benzothiazepinones as Sodium Channel Blockers | TRPV1, TRPV4, CACNA1B | GAA 2587/4885RIPK1 2925/4885EPHX2 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.